NVX-COV2373

Summary

Nvx-Cov2373 (CHEMBL5095387) is a phase-3 clinical-stage unknown; indicated across 2 conditions including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095387
Name	NVX-COV2373
Type	Unknown
Max phase	3

Also known as: Covovax vaccine protein antigen, Nvx-cov 2372, Nvx-cov2373, TAK-019, NVX-COV2373

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05249816	PHASE3	COMPLETED	Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
NCT05299359	PHASE3	COMPLETED	A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
NCT05372588	PHASE3	COMPLETED	Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
NCT05463068	PHASE3	COMPLETED	Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
NCT05875701	PHASE3	COMPLETED	Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05925127	PHASE2/PHASE3	COMPLETED	Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
NCT04712110	PHASE1/PHASE2	COMPLETED	A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
NCT05112848	PHASE2	COMPLETED	A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
NCT05775887	PHASE1	COMPLETED	A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.
NCT04834869	Not specified	RECRUITING	COVID-19 Vaccines Safety Tracking (CoVaST)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).